Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients With Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1- Year From Two Phase 3 Studies

Bimzelx (bimekizumab-bkzx) - UCB

https://static1.squarespace.com/static/6642bbced8b22f3bcd7949a5/t/6a05b7ce0e0e4a17617431e0/1778759630269/APL_v29_iS2_Rev4.pdf

Ai Tran1; Lihi Eder2; Philip J. Mease3; Iain B. McInnes4; M. Elaine Husni5; Mitsumasa Kishimoto6; Barbara Ink7; Rajan Bajracharya7; Jason Coarse8; Fabian Proft9

May 26, 2026